GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (OSTO:BINV) » Definitions » 3-Year EPS without NRI Growth Rate

BioInvent International AB (OSTO:BINV) 3-Year EPS without NRI Growth Rate : -23.60% (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is BioInvent International AB 3-Year EPS without NRI Growth Rate?

BioInvent International AB's EPS without NRI for the three months ended in Mar. 2024 was kr-1.29.

During the past 3 years, the average EPS without NRI Growth Rate was -23.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 23.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 13.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of BioInvent International AB was 54.90% per year. The lowest was -89.80% per year. And the median was 11.90% per year.


Competitive Comparison of BioInvent International AB's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, BioInvent International AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's 3-Year EPS without NRI Growth Rate falls into.



BioInvent International AB 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


BioInvent International AB  (OSTO:BINV) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


BioInvent International AB 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


BioInvent International AB (OSTO:BINV) Business Description

Traded in Other Exchanges
Address
Ideongatan 1, The Gamma Building, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB (OSTO:BINV) Headlines

No Headlines